These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32028909)

  • 1. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
    Tokudome N; Koh Y; Akamatsu H; Fujimoto D; Okamoto I; Nakagawa K; Hida T; Imamura F; Morita S; Yamamoto N
    BMC Cancer; 2020 Feb; 20(1):103. PubMed ID: 32028909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).
    Akamatsu H; Koh Y; Okamoto I; Fujimoto D; Bessho A; Azuma K; Morita S; Yamamoto N; Nakagawa K
    Lung Cancer; 2019 May; 131():128-133. PubMed ID: 31027689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
    BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib for the first-line treatment of
    Tu HY; Wu YL
    Future Oncol; 2020 Nov; 16(31):2569-2586. PubMed ID: 32927981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
    Imai H; Kaira K; Suzuki K; Anzai M; Tsuda T; Ishizuka T; Kuwako T; Naruse I; Nemoto K; Uchino J; Morozumi N; Ishihara S; Minato K; Hisada T
    Lung Cancer; 2018 Dec; 126():41-47. PubMed ID: 30527191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
    Huang CH; Ju JS; Chiu TH; Huang AC; Tung PH; Wang CC; Liu CY; Chung FT; Fang YF; Guo YK; Kuo CS; Yang CT
    Int J Cancer; 2022 Feb; 150(4):626-635. PubMed ID: 34558665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
    Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
    BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
    Sonehara K; Kobayashi T; Tateishi K; Morozumi N; Yoshiike F; Hachiya T; Ono Y; Takasuna K; Agatsuma T; Masubuchi T; Matsuo A; Tanaka H; Morikawa A; Hanaoka M; Koizumi T
    Thorac Cancer; 2019 May; 10(5):1078-1085. PubMed ID: 31006178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
    Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.
    Ricciuti B; Baglivo S; De Giglio A; Chiari R
    Ther Adv Respir Dis; 2018; 12():1753466618808659. PubMed ID: 30355049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O; Kaira K; Mouri A; Shiono A; Hashimoto K; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Cancer Chemother Pharmacol; 2019 May; 83(5):817-825. PubMed ID: 30758646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
    Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
    Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with
    Zhao J; Bai H; Wang X; Wang Y; Duan J; Chen H; Xue Z; Tian Y; Cseh A; Huang DC; Wu YL; Wang J
    Future Oncol; 2022 Apr; 18(12):1485-1497. PubMed ID: 35114807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.